Earnings Call Intelligence Subscribe
Home › Call Sheets › CI › Q2'26
Call sheet · Q2'26

Cigna Group (CI)

Q2'26 earnings call · held July 30, 2026 · compared with the Q1'26 call · management-credibility review
8/12
Disclosure score
2 high, 5 medium, 2 low flags
Financial quality
Bottom line
The sleeper story is that Cigna is essentially harvesting PBM margins to fund specialty growth, with biosimilar adoption accelerating the geographic shift of earnings from pharmacy benefits to specialty faster than planned. The Street sees an EPS beat and guidance raise, but that masks a PBM business that's structurally deteriorating with 'modestly below' expectations performance and mysteriously vaguer retention metrics. The binding constraint is their ability to transition to the Signature model without bleeding more PBM share, especially when management admits 'the magnitude of the benefit we saw in second quarter is not expected to repeat.' Most revealing quote: 'PBS tracking modestly below our earlier assumptions due to the shift in economics.' My view changes if they provide specific 2027 retention numbers above 95% with dollar values attached.

The 30-second version

  • Specialty generics and biosimilars are cannibalizing PBM margins but driving massive specialty growth
  • The obvious EPS beat masks a deteriorating PBM business that's being papered over by specialty strength
  • Management stopped disclosing specific retention rates and switched to vague 'mid-90s or higher' language

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue$68.5B (Q1, +9% YoY)$71.7B (Q2, +5% YoY)Sequential growth but YoY deceleration
Adjusted EPS$7.79 (Q1, +16% YoY)$7.78 (Q2, comparable YoY)Flat sequentially despite seasonality
Evernorth Revenue$58.4B (Q1, +9% YoY)$61.5B (Q2, +6% YoY)300 bps YoY growth deceleration
Specialty & Care Pre-tax Earnings$1.1B (Q1, +20% YoY)$1.1B (Q2, +22% YoY)Accelerating growth
PBM Pre-tax Earnings$394M (Q1, -28% YoY)$609M (Q2, down YoY)Sequential recovery but structural pressure
Cigna Healthcare Revenue$11.5B (Q1, +10% YoY)$11.8B (Q2, +10% YoY)Stable growth
Cigna Healthcare Pre-tax Earnings$1.5B (Q1, +18% YoY)$1.3B (Q2, +17% YoY)Slight deceleration
Medical Care Ratio79.8% (Q1)84.5% (Q2)+470 bps deterioration
Operating Cash Flow$1.1B (Q1)In line with expectations (Q2)No specific number given
Debt-to-Cap Ratio42.3% (Q1)42.8% (Q2)+50 bps increase

Accountability tracked

8 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full CI Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.